Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02332850 · ClinicalTrials.gov registry record · Phase 1

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Thomas Martin, MD.

Active
Registry status
Phase 1
Development phase
83
Enrollment target
6
Study locations

NCT02332850 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Thomas Martin, MD. The registered enrollment target is 83 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02332850, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Thomas Martin, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
83 participants
Enrollment target
6
Study locations

Study Summary

This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide may be a better treatment for patients with multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Carfilzomib
  • BIOLOGICAL Isatuximab

Study Locations (6)

California

  • University of California, San Francisco - San Francisco

Colorado

  • Colorado Blood Cancer Institute - Denver

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • Icahn School of Medicine at Mount Sinai - New York

Tennessee

  • Sarah Cannon Cancer Center - Nashville

Ontario

  • Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2015-01-21
Est. Completion 2025-12-31
Phase Phase 1

Sponsor

Thomas Martin, MD

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02332850

The ClinicalTrials.gov registry entry for NCT02332850 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The listed sponsor is Thomas Martin, MD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT02332850 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, New Jersey.

Frequently Asked Questions

What is clinical trial NCT02332850 about?

NCT02332850 is a clinical study titled "Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma". This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment ...

What is the current status of trial NCT02332850?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2015-01-21. Estimated completion is 2025-12-31.

What conditions does trial NCT02332850 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02332850?

The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Isatuximab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02332850?

This trial is sponsored by Thomas Martin, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02332850 being conducted?

This trial has 6 study locations across California, Colorado, New Jersey, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.